Search Results - Quanli Han

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma

    Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma by Qi Wang, Zhi Cui, Muhong Deng, Guoqing Zhang, Fangfang Jing, Yue Ma, Fang Pang, Quanli Han

    Published 2025-07-01

    BackgroundNimotuzumab has shown promising efficacy in esophageal squamous cell carcinoma (ESCC). However, the efficacy and safety of nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for patients with advanced ESCC remain unclear.MethodsWe performed a real world study...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: